The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...